InvestorLens

KRYS — KRYSTAL BIOTECH INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying KRYS?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 1 buying vs 1 selling last quarter
36
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their KRYS position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ray Dalio)
  • +4 tracked investors reported holding KRYS at their latest filing
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About KRYSTAL BIOTECH INC (KRYS)

KRYSTAL BIOTECH INC (KRYS) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ray Dalio (Bridgewater Associates), valued at $12M. Across recent filings, tracked investors recorded 2 new positions, 2 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in KRYS

80
/100
Strong Institutional Accumulation
Added / Increased4
Reduced0
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track KRYS

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

KRYS Ownership Composition

How KRYSTAL BIOTECH INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
100% of tracked value
Institutions
4
tracked investors
Total Reported
$25.1M
combined 13F value
Sectors1
  • Other100.0%
Other(4)
100.0%

Tracked investors reporting KRYS

  • Ray DalioMar 31, 2026
    Bridgewater Associates
    Shares
    46.4K
    Value
    $12M
    % Portfolio
    0.05%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    32.1K
    Value
    $8.3M
    % Portfolio
    0.00%
  • Paul Tudor JonesMar 31, 2026
    Tudor Investment Corp
    Shares
    14.5K
    Value
    $3.7M
    % Portfolio
    0.01%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    4.1K
    Value
    $1.1M
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold KRYS?
4 tracked institutional investors disclosed a position in KRYS (KRYSTAL BIOTECH INC) in their most recent 13F filing.
Who is the largest institutional holder of KRYS?
Ray Dalio, Bridgewater Associates, holds the largest disclosed position in KRYS, valued at $12M.
Did institutional ownership of KRYS increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 2 increased, 0 reduced, and 1 fully exited KRYS.
Where does this KRYS ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
KRYS (KRYSTAL BIOTECH INC) — Institutional Holders & 13F — InvestorLens